Edesa Biotech launches underwritten public offering of shares, warrants
EDSA•Use of proceeds
Net proceeds are earmarked for general corporate purposes, including R&D and manufacturing expenses.
Underwritten public offering launched
Edesa Biotech launched an underwritten public offering of common shares or pre-funded warrants with accompanying common share warrants.
Underwriters receive a 30-day option to buy up to 15% more common shares or pre-funded warrants with accompanying common share warrants.
Guggenheim Securities serves as sole book-running manager.
